<DOC>
	<DOCNO>NCT00652288</DOCNO>
	<brief_summary>The aim study evaluate variation pharmacokinetic pharmacodynamic property rapid-acting insulin analog give bolus subcutaneous insulin infusion pump typically encounter care child type 1 diabetes . The specific factor investigation : - effect puberty - type insulin analog - site catheter insertion - age catheter</brief_summary>
	<brief_title>Evaluation Pharmacokinetics Pharmacodynamic Properties Rapid-Acting Insulin Analogs</brief_title>
	<detailed_description>The aim study evaluate variation pharmacokinetic ( determined serum free insulin concentration ) pharmacodynamic ( determine glucose infusion rate require maintain euglycemia euglycemic clamp ) property rapid act insulin analog give bolus subcutaneous insulin infusion pump typically encounter care child type 1 diabetes . The specific factor investigate effect puberty ( pre- vs. pubertal ) , type insulin analog ( lispro aspart insulin ) , site catheter insertion ( gluteal vs. abdominal ) , age catheter ( fresh insertion vs. three-day duration ) Our hypothesis peak ( Imax ) area curve ( IAUC ) serum free insulin concentration , peak glucose infusion rate require maintain euglycemia ( GIRmax ) area curve ( GIRAUC ) vary base condition , child give weight-based dose . We also evaluate pharmacokinetic pharmacodynamic property Aspart Lispro insulin use basal-bolus regimen insulin Detemir Glargine , new basal insulin analog , give separate injection combine single injection adolescent patient Type 1 DM . We hypothesize peak ( IMAX ) area curve ( IAUC ) serum insulin concentration , peak glucose infusion rate require maintain euglycemia ( GIRMAX ) area curve ( GIRAUC ) Aspart/Lispro bolus , similar Aspart/Lispro combine syringe insulin Detemir/Glargine , compare Aspart/Lispro Detemir/Glargine give two separate injection .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin , Short-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Age 817 ( inclusive ) , 15 prepubertal 60 pubertal ; 2 . Clinical diagnosis T1D ( base clinical presentation , insulin dependence , and/or history ketosis ; 3 . Diagnosis T1D least one year 's duration ; 4 . On CSII therapy least three month ; 5 . HbA1c 6.58.0 % , inclusive ; 6 . Body mass index &lt; 95 % age gender ; 7 . Meeting minimum weight requirement least 17.6 kg ( prepubertal subject ) 34.6 kg ( pubertal subject ) 8 . Ability comprehend write spoken English 1 . Any medical disease aside T1D treat hypothyroidism 2 . Receiving medication besides insulin levothyroxine 3 . Female subject reproductive potential may pregnant , breast feeding , consistently utilize barrier method abstinence contraception 4 . Inability comprehend write spoken English 5 . Any condition , judgement investigator , would interfere subject 's parent ' ability provide inform consent investigator 's ability perform study</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Type I Diabetes Mellitus</keyword>
</DOC>